Can COVID-19 Cause Myasthenia Gravis?

A growing body of case reports and clinical studies links SARS-CoV-2 infection to the development of new-onset myasthenia gravis, a condition in which the immune system attacks the communication points between nerves and muscles. The connection is not yet proven beyond doubt in the way a large randomized trial would demonstrate, but the pattern across dozens of documented cases is striking enough that neurologists now treat it as a plausible trigger. What makes the relationship particularly interesting is that it fits within a broader, long-recognized phenomenon of viral infections setting off autoimmune neuromuscular disease.

What the Case Reports Show

Since the early waves of the pandemic, clinicians worldwide have reported patients developing myasthenia gravis days to weeks after a confirmed COVID-19 infection. A case-report-based review analyzing 18 of these patients found that the time between COVID-19 and the appearance of MG symptoms ranged from 5 to 56 days, with a median of about 17 days. The patients spanned a wide age range, from 19 to 83 years old, with a roughly even split between men and women. Most developed generalized MG rather than the milder ocular-only form, and the vast majority tested positive for antibodies against the acetylcholine receptor, the hallmark blood marker of the disease.¹

Individual cases fill in the clinical picture. A 19-year-old woman developed eye and throat symptoms 13 days after testing positive for SARS-CoV-2. Over the following three months, her condition worsened into generalized MG complicated by a myasthenic crisis, a life-threatening episode of severe muscle weakness. High levels of anti-acetylcholine receptor antibodies were found in her blood, and specialized nerve-stimulation tests confirmed the diagnosis.² At the other end of the age spectrum, a 78-year-old woman developed neck muscle fatigue and upper-limb weakness after COVID-19, with the unusual finding of antibodies against both the acetylcholine receptor and MuSK, a second protein at the nerve-muscle junction. Having both antibodies at once is rare even in standard MG and made her case particularly notable.³

A separate analysis of eight early cases, including both published reports and one new patient, found a mean age of about 56 years, with most patients presenting generalized disease and positive anti-acetylcholine receptor antibodies.⁴ That question in the paper’s own title captures the honest state of things: temporal association is clear, but a direct causal chain remains difficult to prove definitively for any individual patient.

Why a Virus Might Trigger an Autoimmune Disease

The leading explanation is molecular mimicry. When the immune system mounts its response to SARS-CoV-2, it generates antibodies and immune cells trained to recognize pieces of the virus. If parts of the virus happen to resemble proteins at the neuromuscular junction, those same antibodies or immune cells can mistakenly target the body’s own tissue. This cross-reactivity has been proposed as one of the key mechanisms by which COVID-19 triggers autoimmune disorders, along with a broader loss of immune tolerance during severe infection.⁵

SARS-CoV-2 is far from the first virus suspected of triggering MG. As far back as 1981, researchers documented five patients whose myasthenia symptoms began within weeks of a proven viral infection, raising the question of whether viruses could act as an environmental trigger for the disease.⁶ COVID-19 fits into a broader pattern in which viral infections are associated with direct injury to peripheral nerves, autoimmune neuromuscular disorders like Guillain-Barré syndrome, and potentially chronic neurodegenerative conditions.⁷ What distinguishes SARS-CoV-2 is the sheer scale of exposure: billions of infections worldwide means even a rare autoimmune side effect will produce a visible cluster of cases.

Population-Level Evidence

Beyond individual case reports, at least one cross-sectional study has tried to quantify the trend. Researchers enrolled 359 new-onset MG patients seen at their center, comparing 165 diagnosed before the COVID-19 pandemic to 194 diagnosed afterward. The post-outbreak group was not only larger but showed a spike in cases within the first three months after the outbreak began. Roughly 40% of the post-outbreak patients had evidence of pulmonary inflammation, and nearly 90% had received a COVID-19 vaccine, though disentangling the effects of infection and vaccination was not the study’s primary aim.⁸

The same study found that post-outbreak patients tended to have a shorter disease duration at their first visit and lower baseline severity scores, which could suggest earlier detection or milder initial disease. Younger age at onset, higher baseline disability scores, and having the ocular-only form of MG were independent predictors of clinical improvement in the post-outbreak group.⁸ These findings hint that post-COVID MG may, on average, carry a somewhat more favorable prognosis than MG arising from other triggers, though the evidence is still early.

What Happens to People Who Already Have MG

The question isn’t only whether COVID-19 can trigger new MG. For the hundreds of thousands of people already living with the disease, infection with SARS-CoV-2 poses a distinct and serious risk. Infections of any kind are a well-known trigger for MG flares and crises, and COVID-19 proved no exception.⁹

The CARE-MG study, published in The Lancet Neurology, gathered data on 91 MG patients who contracted COVID-19. Worsening of MG or outright myasthenic crisis requiring rescue therapy occurred in about 40% of them. Rescue therapy in this context means treatments like intravenous immunoglobulin or plasma exchange. While 43% of patients recovered fully or were discharged home, roughly a quarter of the patients in the study died from COVID-19.¹⁰ That mortality rate, collected mostly during the earlier and deadlier pandemic waves before vaccination was widely available, underscores how vulnerable this patient population can be.

Even a mild COVID-19 infection can be enough to push someone with MG into crisis. One case described a patient who presented to the emergency department with a myasthenic crisis triggered by COVID-19 despite having no other significant clinical problems from the infection itself and unremarkable lung imaging.¹¹ The exacerbations tend to come quickly. In infected MG patients, flares developed at a median of about 14 days after contracting COVID-19.¹²

Treatment Considerations When Both Conditions Overlap

Managing MG in a patient who also has COVID-19 requires careful balancing. Many MG patients take immunosuppressive drugs to keep their immune system from attacking the neuromuscular junction, but those same drugs could theoretically make a viral infection worse. The evidence, fortunately, has been somewhat reassuring on most fronts.

A review of treatment options found that acetylcholinesterase inhibitors, the frontline medications for MG symptoms, are generally safe during COVID-19. Corticosteroids were also considered safe and in some cases even beneficial, given that they can reduce the inflammatory damage of severe COVID-19. Other commonly used immunosuppressive drugs appeared to be safe as well, with one significant exception: rituximab, a drug that depletes B cells. Because B cells are critical to fighting viral infections, patients on rituximab faced a higher risk of severe COVID-19.¹³

A case series from Indonesia added a counterintuitive finding: among MG patients who contracted COVID-19, the one patient who was not on corticosteroids or immunosuppressant therapy was the one who experienced a worsening of MG symptoms, while those already taking immunosuppressive medication did not have MG flares.¹⁴ This is a small series and shouldn’t be over-interpreted, but it aligns with the broader message that abruptly stopping immunosuppressive treatment out of fear of COVID-19 may do more harm than good.

COVID-19 Vaccination and Myasthenia Gravis

Vaccines work by mimicking part of an infection, so it’s reasonable to wonder whether COVID-19 vaccines might also trigger MG. The evidence here is thin but worth knowing about. As of early reports, new-onset MG after SARS-CoV-2 vaccination had been rarely documented.¹⁵ One review counted only three published cases of new-onset MG and two cases of severe MG exacerbation linked to COVID-19 vaccination, noting that most studies confirmed the overall safety of vaccination in MG patients.¹⁶

In a retrospective study of 80 MG patients who received SARS-CoV-2 vaccines, 5% experienced an exacerbation within the post-vaccine window period.¹⁷ That number sounds nontrivial, but MG exacerbations can happen for many reasons, and 5% over a post-vaccination window is not dramatically out of line with the background rate of flares in this disease. Neurologists have debated the safety of vaccines in MG patients for years, long before COVID-19. The general consensus remains that the risk of the infection itself far outweighs the small risk of a vaccine-related flare, particularly given the mortality data from the CARE-MG study.

The cross-sectional study mentioned earlier also noted that nearly 90% of its post-outbreak new-onset MG patients had been vaccinated, which complicates the picture. When nearly everyone in a population has been both infected and vaccinated within a narrow time window, attributing new-onset MG specifically to the virus versus the vaccine becomes extremely difficult.⁸ Researchers are still working to untangle this.

Recognizing Post-COVID Myasthenia Gravis

If you’ve had COVID-19 and begin experiencing new symptoms like drooping eyelids, double vision, difficulty swallowing, slurred speech, or unusual muscle weakness that worsens with activity and improves with rest, those symptoms should prompt evaluation for MG. The classic pattern of fatigable weakness, where muscles work fine at first but tire quickly, is distinctive. Three patients in one case series illustrated the range of presentations: a 61-year-old woman developed progressive difficulty swallowing, nasal speech, drooping eyelids, and weakness about six weeks after COVID-19; a 57-year-old man had similar symptoms just 10 days after infection; and a 38-year-old woman presented with fatigue, drooping eyelids, and swallowing difficulty four weeks out. All three tested positive for anti-acetylcholine receptor antibodies.¹⁸

The typical workup involves a blood test for antibodies against the acetylcholine receptor (and sometimes MuSK), nerve conduction studies that look for a characteristic pattern of decreasing muscle response with repeated stimulation, and clinical assessment of fatigable weakness. The good news is that post-COVID MG appears to respond to the same treatments as MG from any other cause: acetylcholinesterase inhibitors for symptom management, immunosuppressive therapy to control the underlying autoimmune process, and rescue therapies like plasma exchange or intravenous immunoglobulin for severe flares or crises.

Why the Link Is Hard to Prove Definitively

MG is rare, affecting roughly 15 to 25 people per 100,000 in most populations. That rarity means it will always be hard to run the kind of massive controlled study that could definitively prove causation rather than association. The current evidence relies heavily on case reports and case series, which can show that two things happen close together in time but cannot rule out coincidence. When a disease affects billions of people, as COVID-19 has, some portion of those billions would have developed MG regardless of whether they caught the virus.

That said, the pattern is difficult to dismiss. The consistent latency of a few weeks between infection and symptom onset, the presence of the same antibodies found in classical MG, the biologically plausible mechanism of molecular mimicry, and the precedent of other viruses triggering MG all point in the same direction. The cross-sectional data showing a measurable increase in new-onset MG after the pandemic began adds a population-level signal to the individual case reports. Most neurologists who have published on this topic treat the association as real and clinically relevant, even while acknowledging that definitive proof may never arrive for a rare complication of a common infection.

One Rare Complication Among Many

Post-COVID MG belongs to a broader family of autoimmune and neurological conditions that have been linked to SARS-CoV-2 infection. Guillain-Barré syndrome, an autoimmune attack on peripheral nerves, attracted attention earlier in the pandemic. Autoimmune encephalitis, inflammatory neuropathies, and various other conditions have also been reported after COVID-19. The neuromuscular junction, where MG strikes, is just one of many sites in the nervous system that can become collateral damage when the immune system overshoots its response to the virus.⁷

One especially unusual post-COVID MG case involved a patient who was found to have a thymoma, a tumor of the thymus gland, discovered during the workup for new MG symptoms after COVID-19. The thymus plays a central role in training immune cells, and thymomas are a known but uncommon association with MG in general. Whether COVID-19 unmasked an existing thymoma by tipping the immune balance, or whether the sequence was coincidental, remains unclear. The patient was ultimately managed with surgical removal of the thymoma, an approach that has long been part of MG treatment when a thymoma is present.⁵

For anyone living with MG or newly diagnosed after COVID-19, the practical takeaway is straightforward: the disease is treatable with established therapies, vaccination remains recommended because the risks of infection are far greater, and new neuromuscular symptoms developing in the weeks after any significant infection deserve prompt medical evaluation rather than a wait-and-see approach.

1
PubMed Central. Autoimmune myasthenia gravis and COVID-19. A case report-based review.
2
PubMed Central. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review
3
Internal Medicine. Double-seropositive Myasthenia Gravis Following COVID-19
4
BMJ Case Reports. Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?
5
International Journal of Surgery Case Reports. Management of thymomatous myasthenia gravis – Case report of a rare Covid19 infection sequelae
6
PubMed. Myasthenia gravis following viral infection
7
PubMed Central. Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections
8
PubMed Central. The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study
9
SpringerLink. Myasthenia gravis at the crossroad of COVID-19: focus on immunological and respiratory interplay
10
The Lancet Neurology. COVID-19 associated risks and effects in myasthenia gravis (CARE-MG)
11
PubMed Central. Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report
12
AJMC. COVID-19 Infection Raises Myasthenia Gravis Exacerbation Risk, Study Finds
13
PubMed Central. TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE
14
eNeurologicalSci. Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia
15
PubMed Central. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature
16
PubMed Central. Myasthenia Gravis Exacerbation Following Immunization With the BNT162b2 mRNA COVID-19 Vaccine: Report of a Case and Review of the Literature
17
PubMed Central. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients
18
Elsevier / PubMed Central. Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases